Journal article
Reldesemtiv in Amyotrophic Lateral Sclerosis
Abstract
Importance: Treatment options for amyotrophic lateral sclerosis (ALS) remain suboptimal. Results from a phase 2 study of reldesemtiv in ALS suggested that it may slow disease progression.
Objective: To assess the effect of reldesemtiv vs placebo on functional outcomes in ALS.
Authors
Shefner JM; Cudkowicz ME; Genge A; Hardiman O; Al-Chalabi A; Andrews JA; Chio A; Corcia P; Couratier P; de Carvalho M
Journal
JAMA Neurology, Vol. 82, No. 5, pp. 477–485
Publisher
American Medical Association (AMA)
Publication Date
May 1, 2025
DOI
10.1001/jamaneurol.2025.0241
ISSN
2168-6149